Personalized Medicine Decision-Making in a Virtual Clinical Setting
- Conditions
- Deep Vein ThrombosisBlood Clots
- Registration Number
- NCT02108041
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Brief Summary
Background:
-How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice.
Objective:
-To study how physicians make personalized treatment decisions
Eligibility:
-Healthy adult primary care physicians who are internal (or family) medicine residents.
Design:
* Participants will complete a screening form.
* Participants will put on a headset, called a head-mounted display, showing a virtual reality environment.
* The environment will contain an exam room and the virtual patient.
* After interacting with the virtual patient, participants will complete a series of survey measures.
* Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.
- Detailed Description
This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 196
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial/ethnic and SES backgrounds Outcome measurements are assessed on the same date of the study visit. To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial /ethnic and SES backgrounds
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Michigan State University
🇺🇸Flint, Michigan, United States
Johns Hopkins School of Medicine
🇺🇸Baltimore, Maryland, United States
Harvard School of Public Health
🇺🇸Boston, Massachusetts, United States
Columbia University
🇺🇸New York, New York, United States
University of Oregon
🇺🇸Eugene, Oregon, United States